Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial

Kidney International Reports

Volumn 2, Issue 3, 2017, Pages 380-389

  Bressendorff, Iain ^a   Hansen, Ditte ^b,c   Schou, Morten ^b   Silver, Burton ^d   Pasch, Andreas ^e   Bouchelouche, Pierre ^f   Pedersen, Lise ^g   Rasmussen, Lars Melholt ^h   Brandi, Lisbet ^a  

^a HILLERØD HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

^d Intra Cellular Diagnostics Inc   (United States)

^e UNIVERSITY OF BERN   (Switzerland)

^f KØGE HOSPITAL   (Denmark)

^g HOLBÆK HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

calcification propensity; chronic kidney disease; magnesium

Indexed keywords

EID: 85021271859     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2016.12.008     Document Type: Article

References (36)

1. Coresh, J., Selvin, E., Stevens, L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007), 2038–2047.
2. Go, A.S., Chertow, G.M., Fan, D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
3. Moe, S.M., Chen, N.X., Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 19 (2008), 213–216.
4. London, G.M., Guerin, A.P., Marchais, S.J., et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003), 1731–1740.
5. Van Laecke, S., Nagler, E.V., Verbeke, F., et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 126 (2013), 825–831.
6. Sakaguchi, Y., Fujii, N., Shoji, T., et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 85 (2014), 174–181.
7. Sakaguchi, Y., Fujii, N., Shoji, T., et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PloS One, 9, 2014, e116273.
8. Kanbay, M., Yilmaz, M.I., Apetrii, M., et al. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol 36 (2012), 228–237.
9. Ishimura, E., Okuno, S., Yamakawa, T., et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 20 (2007), 237–244.
10. Joao Matias, P., Azevedo, A., Laranjinha, I., et al. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif 38 (2014), 244–252.
11. Fein, P., Weiss, S., Ramos, F., et al. Serum magnesium concentration is a significant predictor of mortality in peritoneal dialysis patients. Adv Perit Dial 30 (2014), 90–93.
12. Kurita, N., Akizawa, T., Fukagawa, M., et al. Contribution of dysregulated serum magnesium to mortality in hemodialysis patients with secondary hyperparathyroidism: a 3-year cohort study. Clin Kidney J 8 (2015), 744–752.
13. de Roij van Zuijdewijn, C.L., Grooteman, M.P., Bots, M.L., et al. Serum magnesium and sudden death in European hemodialysis patients. PloS One, 10, 2015, e0143104.
14. Sakaguchi, Y., Iwatani, H., Hamano, T., et al. Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int 88 (2015), 833–842.
15. Massy, Z.A., Drueke, T.B., Magnesium and cardiovascular complications of chronic kidney disease. Nat Rev Nephrol 11 (2015), 432–442.
16. Montezano, A.C., Zimmerman, D., Yusuf, H., et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56 (2010), 453–462.
17. Kircelli, F., Peter, M.E., Sevinc Ok, E., et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 27 (2012), 514–521.
18. Louvet, L., Buchel, J., Steppan, S., et al. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 28 (2013), 869–878.
19. Montes de Oca, A., Guerrero, F., Martinez-Moreno, J.M., et al. Magnesium inhibits Wnt/beta-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PloS One, 9, 2014, e89525.
20. Zelt, J.G., McCabe, K.M., Svajger, B., et al. Magnesium modifies the impact of calcitriol treatment on vascular calcification in experimental chronic kidney disease. J Pharmacol Exp Ther 355 (2015), 451–462.
21. Turgut, F., Kanbay, M., Metin, M.R., et al. Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. Int Urol Nephrol 40 (2008), 1075–1082.
22. Mortazavi, M., Moeinzadeh, F., Saadatnia, M., et al. Effect of magnesium supplementation on carotid intima-media thickness and flow-mediated dilatation among hemodialysis patients: a double-blind, randomized, placebo-controlled trial. Eur Neurol 69 (2013), 309–316.
23. Pasch, A., Farese, S., Graber, S., et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 23 (2012), 1744–1752.
24. Smith, E.R., Ford, M.L., Tomlinson, L.A., et al. Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 25 (2014), 339–348.
25. Keyzer, C.A., de Borst, M.H., van den Berg, E., et al. Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol 27 (2016), 239–248.
26. Dahle, D.O., Asberg, A., Hartmann, A., et al. Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients. Am J Transplant 16 (2016), 204–212.
27. Silver, B.B., Development of cellular magnesium nano-analysis in treatment of clinical magnesium deficiency. J Am Coll Nutr 23 (2004), 732S–737S.
28. Haigney, M.C., Silver, B., Tanglao, E., et al. Noninvasive measurement of tissue magnesium and correlation with cardiac levels. Circulation 92 (1995), 2190–2197.
29. Shechter, M., Sharir, M., Labrador, M.J., et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 102 (2000), 2353–2358.
30. Shechter, M., Bairey Merz, C.N., Stuehlinger, H.G., et al. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 91 (2003), 517–521.
31. McBride, B.F., Min, B., Kluger, J., et al. An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence. Ann Noninvasive Electrocardiol 11 (2006), 163–169.
32. Pokan, R., Hofmann, P., von Duvillard, S.P., et al. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br J Sports Med 40 (2006), 773–778.
33. Shechter, M., Saad, T., Shechter, A., et al. Comparison of magnesium status using X-ray dispersion analysis following magnesium oxide and magnesium citrate treatment of healthy subjects. Magnes Res 25 (2012), 28–39.
34. de Seigneux, S., Ponte, B., Berchtold, L., et al. Living kidney donation does not adversely affect serum calcification propensity and markers of vascular stiffness. Transpl Int 28 (2015), 1074–1080.
35. Aghagolzadeh, P., Bachtler, M., Bijarnia, R., et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis 251 (2016), 404–414.
36. Jahnen-Dechent, W., Ketteler, M., Magnesium basics. Clin Kidney J 5:Suppl 1 (2012), i3–i14.